From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Elzasonan structure.svg
Clinical data
Routes of
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
CAS Number
PubChem CID
Chemical and physical data
Molar mass448.4085 g/mol g·mol−1
3D model (JSmol)

Elzasonan (CP-448,187) is a selective 5-HT1B and 5-HT1D receptor antagonist that was under development by Pfizer for the treatment of depression but was discontinued, possibly due to poor efficacy.[1][2][3][4][5] By preferentially blocking 5-HT1B and 5-HT1D autoreceptors, elzasonan is thought to enhance serotonergic innervations originating from the raphe nucleus, thereby improving signaling to limbic regions like the hippocampus and prefrontal cortex and ultimately resulting in antidepressant effects.[3]

See also[edit]


  1. ^ José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. ISBN 978-3-527-31058-6.
  2. ^ Stahl's essential psychopharmacology: neuroscientific basis and practical applications. Cambridge, UK: Cambridge University Press. 2008. ISBN 978-0-521-85702-4.
  3. ^ a b "IngentaConnect 5-HT1 Receptor Augmentation Strategies as Enhanced Efficacy Thera..." August 2008.
  4. ^ Norman, Peter (2002). "Pfizer, Inc.: analysis of patenting 1998 – 2001; Expert Opinion on Therapeutic Patents - 12(5):Pages 725-732 - Informa Healthcare". Expert Opinion on Therapeutic Patents. 12 (5): 725–732. doi:10.1517/13543776.12.5.725.
  5. ^ Kirchhoff, Victoria D.; Nguyen, Ha TT; Soczynska, Joanna K.; Woldeyohannes, Hanna; McIntyre, Roger S. (2009). "Discontinued psychiatric drugs in 2008; Expert Opinion on Investigational Drugs - 18(10):Pages 1431-1443 - Informa Healthcare". Expert Opinion on Investigational Drugs. 18 (10): 1431–1443. doi:10.1517/13543780903184591. PMID 19715445.